Biomea Fusion, Inc.

Listed Company

BMEACIK 0001840439NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-61.80M

Total Assets

$58.57M

Equity

$29.55M

Shares Out

72.30M

Op. Cash Flow

$-70.37M

Business

Biomea Fusion, Inc. is a clinical-stage diabetes and obesity medicines company that discovers and develops oral covalent small molecule drugs. It develops product candidates including icovamenib, a covalent menin inhibitor in Phase II trials, and BMF-650, an oral small-molecule GLP-1 receptor agonist in IND-enabling studies. Its operations center on a proprietary FUSION™ System discovery platform and clinical development programs within a metabolic pipeline, having transitioned away from internal oncology programs. It distributes product candidates through clinical trials, relies on third‑party manufacturing, and plans U.S. commercialization with partner arrangements for other markets.

Summary from filing dated 2025-03-31

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	62	118	103	63	28
General and administrative	19	26	24	21	14
Impairment of long-lived assets	2	0	0	—	—
Total operating expenses	84	144	126	84	42
Loss from operations	−84	−144	−126	−84	−42
Change in fair value of common warrant liability	20	0	0	—	—
Interest and other income, net	2	6	9	2	100,000
Net loss	−62	−138	−117	−82	−42
Unrealized gain on investments, net	—	—	1,000	9,000	−10,000
Comprehensive loss	−62	−138	−117	−82	−42
Net loss per common share, basic	−1.18	−3.83	−3.44	−2.8	−1.74
Net loss per common share, diluted	−1.18	−3.83	−3.44	−2.8	−1.74
Weighted-average number of common shares used to compute basic net loss per common share	52	36	34	29	24
Weighted-average number of common shares used to compute diluted net loss per common share	52	36	34	29	24

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	56	58	177	112	146
Prepaid expenses and other current assets	2	10	2	5	3
Total current assets	58	68	179	118	177
Property and equipment, net	153,000	4	5	6	3
Restricted cash	369,000	369,000	370,000	351,000	351,000
Other non-current assets	0	619,000	6	3	1
Operating lease right-of-use assets	0	7	10	2	3
Total assets	59	80	200	129	186
Accounts payable	3	13	7	7	1
Accrued expenses and other current liabilities	6	7	14	12	3
Operating lease liabilities, current	1	2	2	618,000	565,000
Total current liabilities	11	22	23	19	5
Operating lease liabilities, non-current	128,000	7	8	2	2
Warrant liability, non-current	18	0	—	—	—
Total liabilities	29	28	31	21	7
Commitments and contingencies (Note 8)	—	—	—	—	—
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 0 shares issued and outstanding as of December 31, 2025 and December 31, 2024	—	—	—	—	—
Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 72,299,440 and 36,310,713 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	7,000	4,000	4,000	3,000	3,000
Additional paid-in capital	479	439	418	240	229
Accumulated deficit	−449	−387	−249	−132	−50
Total stockholders' equity	30	52	169	109	179
Total liabilities and stockholders' equity	59	80	200	129	186

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−62	−138	−117	−82	−42
Depreciation expense	1	2	2	700,000	200,000
Non-cash operating lease expense	2	3	3	571,000	704,000
Stock-based compensation expense	10	19	14	10	6
Net amortization of premiums and accretion of discounts on investments	—	—	1,000	144,000	516,000
Prepaid expenses and other current assets	8	−8	2	−2	−3
Other non-current assets	619,000	5	−2	—	—
Accounts payable	−10	6	3	3	640,000
Accrued expenses and other current liabilities	−255,000	−7	2	9	2
Operating lease liabilities	−2	−2	−2	−565,000	−589,000
Net cash used in operating activities	−70	−120	−97	−62	−35
Purchase of property and equipment	—	−362,000	−3	−1	−3
Maturities of investments	—	—	1	28	8
Net cash (used in) provided by investing activities	—	−362,000	−2	27	−33
Proceeds from issuance of common stock under at the market equity offering program, net of offering costs	5	—	162	—	—
Proceeds from issuance of common stock, common warrants and pre-funded warrants, net of offering costs	63	—	162	—	—
Proceeds from stock options exercised and purchases under the employee stock purchase plan	159,000	2	2	1	468,000
Net cash provided by financing activities	68	2	164	1	153
Net (decrease) increase in cash, cash equivalents, and restricted cash	−2	−119	65	−34	84
Acquisition of operating lease right-of-use assets	—	—	6	—	3
Acquisition of property and equipment in accounts payable and accrued liabilities	—	7,000	—	3	—
Remeasurement of operating lease right-of-use assets and lease liability	5	—	6	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro